Proquad Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of routine childhood vaccination programs, increasing public health awareness initiatives, availability of combination vaccines, growth in pediatric healthcare infrastructure, government-supported immunization funding.

The growth in the forecast period can be attributed to expansion of global vaccination coverage targets, rising investments in next-generation vaccine development, increasing focus on immunization compliance monitoring, growth of public-private vaccination partnerships, improving vaccine distribution logistics. Major trends in the forecast period include increasing adoption of combination vaccines, rising focus on pediatric immunization coverage, expansion of national immunization programs, growing emphasis on cold chain optimization, improved vaccine safety and monitoring systems.

The rising incidence of measles and chickenpox is expected to drive growth in the ProQuad market in the coming years. Measles is a highly contagious viral infection marked by fever, cough, and a red rash, while chickenpox, caused by the Varicella-zoster virus, presents with an itchy blister-like rash. Both diseases are preventable through vaccination. Recent increases in measles and chickenpox cases are linked to declining vaccination rates, misinformation about vaccines, increased global travel, and outbreaks among unvaccinated populations, contributing to the re-emergence of these preventable illnesses. ProQuad, a combination vaccine for measles, mumps, rubella, and varicella (MMRV), provides immunity in a single dose, reducing the risk of infection, controlling outbreaks, and preventing complications associated with these diseases. For example, in May 2024, the World Health Organization reported 56,634 measles cases and four deaths across 45 of 53 countries in the WHO European Region during the first quarter of the year, compared with 61,070 cases and 13 deaths reported by 41 countries throughout 2023. Therefore, the rising incidence of measles and chickenpox is fueling ProQuad market growth.

Increasing healthcare expenditures are also expected to support the ProQuad market. Healthcare expenditures encompass all spending on medical services, products, and public health activities, and are rising due to factors such as the growing prevalence of chronic diseases, an aging population, medical technology advancements, and greater demand for healthcare services. These expenditures help fund immunization programs, expand vaccine accessibility, promote public awareness, and provide the infrastructure and insurance coverage needed for widespread adoption. For instance, in May 2023, the UK Office for National Statistics reported that healthcare expenditure in the UK totaled approximately $362 billion (£292 billion), reflecting a 5.6% nominal increase. Long-term health and social care expenditure also rose by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is driving ProQuad market growth.

Key companies in the ProQuad market are focusing on expanding vaccine administration options, such as intramuscular (IM) delivery, to improve convenience and consistency in immunization practices. IM administration delivers vaccines directly into muscle tissue, allowing faster absorption into the bloodstream. For example, in March 2023, Merck & Co. Inc., a U.S.-based pharmaceutical company, received FDA approval to add an IM administration option to the U.S. Product Insert for its MMRV vaccine family, including ProQuad. This approval allows healthcare professionals to administer all routinely recommended injectable pediatric vaccines via the same IM route, with M-M-R II, VARIVAX, and ProQuad being the only MMRV vaccines approved for IM use in the U.S. The MMRV family is also licensed for IM administration in the European Union.

Major companies operating in the proquad market are Merck and Co. Inc.

North America was the largest region in the proquad market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proquad market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the proquad market by increasing costs associated with imported biological raw materials, specialized manufacturing equipment, cold chain packaging, and vaccine storage solutions. North America and Europe are most affected due to stringent quality requirements and reliance on cross-border biopharmaceutical supply chains, while emerging markets face higher procurement costs. These tariffs are contributing to increased pricing pressure for healthcare systems and vaccination programs. However, they are also encouraging localized vaccine manufacturing, regional fill-and-finish capabilities, and strengthened domestic supply chains to ensure long-term immunization security.

The proquad market research report is one of a series of new reports that provides proquad market statistics, including proquad industry global market size, regional shares, competitors with a proquad market share, detailed proquad market segments, market trends and opportunities, and any further data you may need to thrive in the proquad industry. This proquad market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Proquad is a combination vaccine that protects against measles, mumps, rubella (MMR), and varicella (chickenpox). By combining multiple vaccines into a single injection, it reduces the number of shots required for immunization. It is primarily used in children, typically given as a single dose to those between 12 months and 12 years of age.

The main indications for Proquad include measles, mumps, rubella, and varicella. The measles component is intended to prevent measles, a highly contagious viral infection, and is administered during childhood as part of the MMR combination vaccine. Proquad is used in pediatric and adult patients and is administered by end users such as healthcare providers, pharmacies, and public health organizations.

The proquad market consists of sales of proquad lyophilized suspension for injection, subcutaneous injection and intramuscular injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.